Article
Biochemistry & Molecular Biology
Ernesto Rossi, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, Silvia Longo, Francesco Deodato, Alessandro Di Stefani, Ketty Peris, Maria Antonietta Gambacorta, Giampaolo Tortora
Summary: BRAF and MEK inhibitors have changed the clinical management of metastatic melanoma, but their combination with radiotherapy needs careful monitoring for potential toxicity. This study reports the successful use of fractionated radiotherapy in metastatic melanoma patients receiving BRAF and MEK inhibitors, without significant adverse events. These results suggest that interruption of targeted therapy during radiotherapy for oligoprogressive disease can be avoided.
Review
Medicine, General & Internal
Morena Fasano, Carminia Maria Della Corte, Marianna Caterino, Mario Pirozzi, Raffaele Rauso, Teresa Troiani, Giulia Martini, Stefania Napolitano, Floriana Morgillo, Fortunato Ciardiello
Summary: In this case report, a patient with recurrent craniopharyngioma harboring BRAF V600E mutation received targeted therapy with a combination of BRAF inhibitor and MEK inhibitor, showing significant clinical improvement and rapid response.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Walid Shalata, Rachel Steckbeck, Ilya Polishchuk, Ahron Yehonatan Cohen, Keren Rouvinov, Margarita Tokar, Ashraf Abu Jama, Omar Abu Saleh, Kim Sheva, Alexander Yakobson
Summary: This case report presents a patient with metastatic melanoma complicated by hyperbilirubinemia. The patient had BRAF V600E-mutated melanoma with metastases in various organs. Due to a lack of guidelines for treating melanoma patients with hyperbilirubinemia, a panel of specialists discussed between treatment initiation and supportive care. The patient eventually received combination therapy with dabrafenib and trametinib, resulting in a significant therapeutic and radiological response.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ji Eun Shin, Ho Jung An, Hyung Soon Park, Hyunho Kim, Byoung Yong Shim
Summary: Studies have shown that the BRAF V600E mutation is common in KRAS wild-type PDAC and can be targeted for treatment, resulting in partial response. Further evidence suggests that short in-frame deletions of BRAF also have oncogenic function.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lili Mao, Ya Ding, Xue Bai, Xinan Sheng, Jie Dai, Zhihong Chi, Chuanliang Cui, Yan Kong, Yun Fan, Yanjun Xu, Xuan Wang, Bixia Tang, Bin Lian, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Caili Li, Jun Guo, Xiaoshi Zhang, Lu Si
Summary: The combination treatment of dabrafenib and trametinib shows long-term survival benefits in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma. The study found a high objective response rate and overall survival rate in these patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
V Subbiah, R. J. Kreitman, Z. A. Wainberg, J. Y. Cho, J. H. M. Schellens, J. C. Soria, P. Y. Wen, C. C. Zielinski, M. E. Cabanillas, A. Boran, P. Ilankumaran, P. Burgess, T. Romero Salas, B. Keam
Summary: This study evaluated the efficacy and safety of dabrafenib plus trametinib in the treatment of BRAF V600E-mutant ATC. The results showed that the combination therapy provided significant clinical benefits and manageable toxicity, leading to improved long-term survival in patients with ATC.
ANNALS OF ONCOLOGY
(2022)
Article
Dermatology
Chang Gon Kim, Miso Kim, Jieon Hwang, Seung Tae Kim, Minkyu Jung, Kyoo Hyun Kim, Kyung Hwan Kim, Jee Suk Chang, Woong Sub Koom, Mi Ryung Roh, Kee Yang Chung, Tae Min Kim, Sang Kyum Kim, Jeeyun Lee, Sang Joon Shin
Summary: This study compared the outcomes of first-line pembrolizumab and dabrafenib/trametinib treatment for patients with advanced melanoma with BRAF mutations. The results showed that first-line pembrolizumab treatment resulted in longer overall survival, suggesting it may be a better treatment option.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Oncology
Alexander Schulz, Jennifer Raetz, Paula C. Karitzky, Lisa Dinter, Julia K. Tietze, Isabell Kolbe, Theresa Kaeubler, Bertold Renner, Stefan Beissert, Friedegund Meier, Dana Westphal
Summary: In the past, metastatic melanoma was often considered incurable, but with the introduction of new therapies, such as BRAF and MEK inhibitors, significant progress has been made in the treatment of this disease. This study compared different combinations of BRAF and MEK inhibitors, with encorafenib/trametinib showing the highest anti-tumor activity in both BRAF- and NRAS-mutated melanoma cells. These findings suggest that this particular combination may be more effective than current standard treatments and warrants further investigation in clinical trials to potentially improve overall responses in melanoma patients.
Article
Oncology
C. Lorimer, L. Cheng, R. Chandler, K. Garcez, V. Gill, K. Graham, W. Grant, S. Sardo Infirri, J. Wadsley, L. Wall, N. Webber, K. H. Wong, K. Newbold
Summary: This study retrospectively evaluated the treatment outcomes of 17 ATC patients with BRAF-V600E mutation, and the results showed that combination therapy with dabrafenib and trametinib was effective and well-tolerated in treating ATC.
Article
Oncology
David Planchard, Benjamin Besse, Harry J. M. Groen, Sayed M. S. Hashemi, Julien Mazieres, Tae Min Kim, Elisabeth Quoix, Pierre-Jean Souquet, Fabrice Barlesi, Christina Baik, Liza C. Villaruz, Ronan J. Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson
Summary: The combination therapy of dabrafenib plus trametinib showed significant and durable clinical benefits in patients with BRAF V600E mutant metastatic non-small cell lung cancer, regardless of previous treatment, with a manageable safety profile. The study also found that the presence of coexisting genomic alterations may influence clinical outcomes and further investigation is needed.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Victoria Atkinson, Caroline Robert, Jean J. Grob, Helen Gogas, Caroline Dutriaux, Lev Demidov, Avinash Gupta, Alexander M. Menzies, Bettina Ryll, Flora Miranda, Hiya Banerjee, Mike Lau, Michele Del Vecchio
Summary: The COMBI-APlus trial demonstrated the effectiveness of an adapted pyrexia management algorithm in treating high-risk resected BRAF V600E/K-mutant melanoma patients, significantly reducing the incidence of severe pyrexia and related adverse outcomes, and helping patients continue their treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Ruoxin Fang, Jun Gong, Zhengkai Liao
Summary: This report describes a case of mutated BRAF(V600E) pulmonary sarcomatoid carcinoma (PSC) patient who relapsed quickly after undergoing surgery and adjuvant chemotherapy. Both chemotherapy and immunotherapy were ineffective, but combined dabrafenib and trametinib treatment produced a 6-month progression-free survival and partial remission. Dabrafenib combined with trametinib offers a potential treatment option for advanced PSC patients with BRAF(V600E) mutations, and large-scale NGS panels can provide additional choices for PSC treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Philippe Saiag, Caroline Robert, Jean -Jacques Grob, Laurent Mortier, Olivier Dereure, Celeste Lebbe, Sandrine Mansard, Florent Grange, Eve-Marie Neidhardt, Thierry Lesimple, Laurent Machet, Christophe Bedane, Herve Maillard, Sophie Dalac-Rat, Alexandra Szenik, Charlee Nardin, Amine Denden, Caroline Dutriaux
Summary: This large prospective study in France investigated the treatment outcomes of BRAF V600-mutant melanoma patients receiving dabrafenib and trametinib combination therapy. The study confirmed previous findings that factors such as lactate dehydrogenase levels, Eastern Cooperative Oncology Group Performance Status, number of metastatic sites, and presence of brain metastasis are associated with progression-free survival in these patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Nora Isberner, Anja Gesierich, David Balakirouchenane, Bastian Schilling, Fatemeh Aghai-Trommeschlaeger, Sebastian Zimmermann, Max Kurlbaum, Alicja Puszkiel, Benoit Blanchet, Hartwig Klinker, Oliver Scherf-Clavel
Summary: This study analyzed the exposure of dabrafenib and trametinib in melanoma patients and its association with adverse events and patient characteristics. The study found that drug exposure was not associated with age, sex, body mass index, or toxicity. Additionally, self-sampling of capillary blood was feasible and a conversion model was developed to estimate serum exposure.
Article
Oncology
Victoria G. Atkinson, Pietro Quaglino, Massimo Aglietta, Michele Del Vecchio, Roberta Depenni, Francesca Consoli, Dimitrios Bafaloukos, Pier Francesco Ferrucci, Skaiste Tulyte, Ivana Krajsova, Paolo A. Ascierto, Rossana Gueli, Ana Arance, Helen Gogas, Hiya Banerjee, Teddy Saliba, Egbert de Jong, Bart Neyns
Summary: Compassionate-use programs allow for retrospective evaluation of treatment patterns and clinical outcomes in real-world settings to validate results from controlled trials. DESCRIBE III study identified lower LDH levels and fewer metastatic sites as baseline characteristics associated with long-term benefit in patients treated with dabrafenib + trametinib.
Article
Oncology
Antonio Omuro, Alba A. Brandes, Antoine F. Carpentier, Ahmed Idbaih, David A. Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bahr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z. Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Summary: This study showed that TMZ + RT had better efficacy than NIVO + RT in newly diagnosed GBM patients with unmethylated MGMT promoter. However, no new safety signals were detected with NIVO in this study.
Article
Oncology
Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui K. Gan, Matthias Preusser, Michael A. Vogelbaum, Erik P. Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S. Macsai, Mark R. Gilbert, Earle E. Bain, Vincent Blot, Peter J. Ansell, Suvajit Samanta, Madan G. Kundu, Terri S. Armstrong, Jeffrey S. Wefel, Clemens Seidel, Filip Y. de Vos, Sigmund Hsu, Andres F. Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard A. Peterson, Craig Gedye, Veronique Bourg, Antje Wick, Walter J. Curran, Minesh P. Mehta
Summary: The use of depatux-m in newly diagnosed glioblastomas (GBMs) with epidermal growth factor receptor gene amplification (EGFR-amp) did not improve overall survival (OS), but showed a longer progression-free survival. There were safety risks associated with the treatment, leading to treatment discontinuation for some patients.
Article
Oncology
A. Bosio, G. Cerretti, M. Padovan, M. Caccese, L. Denaro, F. Chioffi, A. Della Puppa, V. Aldegheri, V. Guarneri, V. Zagonel, G. Lombardi
Summary: The aim of this study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) in patients with recurrent glioblastoma (GBM). The results showed that rechallenge with metronomic TMZ is a well-tolerated option for the treatment of recurrent GBM.
Article
Oncology
Mario Caccese, Isacco Desideri, Marta Padovan, Francesco Bruno, Giulia Cerretti, Alba Fiorentino, Luca Denaro, Franco Chioffi, Alessandro Della Puppa, Marta Maccari, Francesco Cavallin, Marina Coppola, Alice Pittaro, Roberta Ruda, Lorenzo Livi, Giuseppe Lombardi
Summary: In this study, we examined the relationship between baseline thyroid variables and outcomes in IDH-wild type GBM patients treated with regorafenib. The results showed that the baseline fT3/fT4 ratio had a non-linear relationship with survival, and baseline TSH may be a predictor of regorafenib activity.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Clinical Neurology
Giulio Sansone, Lorenzo Pini, Alessandro Salvalaggio, Matteo Gaiola, Francesco Volpin, Valentina Baro, Marta Padovan, Mariagiulia Anglani, Silvia Facchini, Franco Chioffi, Vittorina Zagonel, Domenico D'Avella, Luca Denaro, Giuseppe Lombardi, Maurizio Corbetta
Summary: This study investigated the relationships between the brain's functional topological organization and the location of glioblastoma (GBM), as well as its association with overall survival (OS). The results showed that GBM core and edema preferentially overlapped with specific gray matter and white matter functional networks. Five main distribution patterns of GBM core were identified. Although the involvement of certain functional networks seemed to have some role in predicting survival, network-topology information was overall not very informative about OS.
FRONTIERS IN NEUROLOGY
(2023)
Review
Oncology
Nicolas Crainic, Julia Furtner, Johan Pallud, Franck Bielle, Giuseppe Lombardi, Roberta Ruda, Ahmed Idbaih
Summary: The 2021 WHO classification has improved the diagnostic criteria for rare glial, neuronal, and glioneuronal tumors. These tumors present challenges in terms of diagnosis and therapeutic management, and require multimodal parameters for accurate diagnosis. Complete resection of the tumor is crucial for treatment, and targeting MAPK pathway abnormalities could be a promising approach for novel drugs.
Editorial Material
Oncology
Alberto Bosio, Giuseppe Lombardi
Article
Oncology
S. Giunco, M. Padovan, C. Angelini, F. Cavallin, G. Cerretti, M. Morello, M. Caccese, B. Rizzo, D. d'Avella, A. D. Puppa, F. Chioffi, P. De Bonis, V. Zagonel, A. De Rossi, G. Lombardi
Summary: This study investigated the clinical relevance of TERT gene mutations, single nucleotide polymorphisms, and telomere length in patients with IDH wildtype GBM. The results showed that TERT gene mutations were present in 80.2% of patients, and most patients had the T/T genotype of rs2853669. Patients carrying the C/C or C/T genotype of rs2853669 had better progression-free survival compared to those with the T/T genotype. Overall, TERT gene mutations and telomere length were not correlated with survival in GBM patients, while the genotype of rs2853669 was associated with progression-free survival.
Review
Endocrinology & Metabolism
Marta Padovan, Giulia Cerretti, Mario Caccese, Mattia Barbot, Eleonora Bergo, Gianluca Occhi, Carla Scaroni, Giuseppe Lombardi, Filippo Ceccato
Summary: Despite multimodal treatment, pituitary adenomas can still show a tendency to grow. Temozolomide (TMZ) has been used for the treatment of aggressive pituitary tumors in the past 15 years. The use of TMZ requires a careful balance of different expertise, especially in terms of selection criteria.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM
(2023)
Article
Nutrition & Dietetics
Marina Padovan, Fernando Ribeiro de Senna, Juliana Klein Kimura, Samara Tortorella Nascimento, Antonio Carlos Moretti, Caroline Dario Capitani
Summary: This study proposed a mathematical model to generate a one-month menu that meets the nutritional recommendations of the Workers' Food Program (WFP) in Brazil, with low cost and good quality. The model considered aspects related to eating habits, repetition of dishes, texture combination, and colors of the dishes served. The generated menu met the recommendations of the WFP, providing healthy and nutritionally balanced meals.
Review
Biochemistry & Molecular Biology
Gerardo Caruso, Aristide Nanni, Antonello Curcio, Giuseppe Lombardi, Teresa Somma, Letteria Minutoli, Maria Caffo
Summary: An increase in brain tumor incidence has been observed in industrialized countries, leading to interest in the study of heavy metals and their presence in the environment. Accumulation of heavy metals in the body could increase the risk of various pathologies, including brain tumors, through the generation of reactive oxygen species. Iron, cadmium, lead, nickel, chromium, and mercury levels are significantly elevated in patients with gliomas. This study aims to explore the correlation between heavy metals, their presence in the environment, and glioma tumorigenesis, and provides a literature review.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Mario Caccese, Fabio Busato, Angela Guerriero, Marta Padovan, Giulia Cerretti, Marina Paola Gardiman, Vittorina Zagonel, Giuseppe Lombardi
Summary: Meningiomas, the most common tumors in the central nervous system, are typically treated with surgery. Adjuvant radiotherapy is used for certain cases, but not all patients can undergo further treatment. Tyrosine kinase inhibitors have shown limited success, while bevacizumab and immunotherapy have displayed promising results. Ongoing studies are assessing different therapeutic options for meningiomas. Exploring these treatments and future perspectives is important for improving patient outcomes.
Article
Radiology, Nuclear Medicine & Medical Imaging
Chiara Giraudo, Antonella Modugno, Giacomo Negro, Andrea Dell'Amore, Diego Cecchin, Raffaella Motta, Elisabetta Balestro, Annalisa Boscolo, Fiorella Calabrese, Eleonora Faccioli, Paolo Navalesi, Andrea Vianello, Federico Rea, Roberto Stramare
Summary: Radiomic feature Imc2 was found to be a predictor of allograft rejection in lung transplant, indicating its potential role in predicting rejection.
